We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Download Mobile App


03 Feb 2020 - 06 Feb 2020
01 Mar 2020 - 05 Mar 2020

A Rapid Method for Selecting the Proper Antibiotic to Treat Multidrug Resistant Bacteria

By Labmedica International staff writers
Posted on 12 Dec 2019
Print article
Image: Scanning electron micrograph of carbapenem-resistant Enterobacteriaceae bacteria (Photo courtesy of Stephanie Rossow, Centers for Disease Control and Prevention/Antibiotic Resistance Coordination & Strategy Unit)
Image: Scanning electron micrograph of carbapenem-resistant Enterobacteriaceae bacteria (Photo courtesy of Stephanie Rossow, Centers for Disease Control and Prevention/Antibiotic Resistance Coordination & Strategy Unit)
A new diagnostic approach allows physicians to accurately identify bacterial pathogens and identify the most appropriate antibiotic within a period of hours rather than days.

Multidrug resistant organisms are a serious threat to human health. Fast, accurate antibiotic susceptibility testing (AST) is a critical need in addressing escalating antibiotic resistance, since delays in identifying multidrug resistant organisms increase mortality and use of broad-spectrum antibiotics, further selecting for resistant organisms.

The current gold standard method for "phenotypic" antibiotic susceptibility testing (AST) is growing organisms isolated from the patient in the presence of various antibiotics to see which drug can inhibit growth of the microbe. While such growth-based assays are accurate, they require several days to return results. Newer "genotypic" methods that search bacterial DNA for mutations known to confer drug resistance are quicker but less accurate, since resistance can arise from genetic changes other than those included in the test.

A new approach that combines both phenotypic and genotypic analysis has been developed by investigators at the Broad Institute of the Massachusetts Institute of Technology and Harvard University (Cambridge, MA, USA). This rapid assay combines genotypic and phenotypic AST through RNA detection. The test, which has been named GoPhAST-R (for Genotypic and Phenotypic AST through RNA), classifies bacterial strains with 94–99% accuracy by coupling machine learning analysis of early antibiotic-induced transcriptional changes with simultaneous detection of key genetic resistance determinants.

The method employs machine-learning algorithms to identify the mRNA transcripts that best distinguish drug-sensitive from drug-resistant organisms and integrates this information with analysis of the sequence of mRNA transcripts to reveal whether the bacteria carry key genes known to cause drug resistance.

By performing these analyses on the NanoString (Seattle, WA, USA) prototype Hyb & Seq instrument, the investigators were able to use the GoPhAST-R method to determine antibiotic susceptibility less than four hours after bacteria were positively detected in a blood culture, compared to 28-40 hours using standard clinical laboratory methods. The method was able to detect susceptibility to three major antibiotic classes in clinical use today - carbapenems, fluoroquinolones, and aminoglycosides in five pathogens that often become drug-resistant: Escherichia coli, Klebsiella pneumoniae, Acinetobacter baumannii, Staphylococcus aureus, and Pseudomonas aeruginosa.

"The ability to quickly and accurately identify the best antibiotic would greatly improve the care of patients with infection, while ensuring that our arsenal of antibiotics is deployed intelligently and efficiently," said senior author Dr. Deborah Hung, associate professor of molecular biology at Harvard Medical School.

The GoPhAST-R method was described in the November 25, 2019, online edition of the journal Nature Medicine.

Related Links:
Broad Institute

Print article


Industry News

view channel
Image: BioProfile FLEX2 On-Line Autosampler (Photo courtesy of Nova Biomedical)

Nova Biomedical Launches New BioProfile FLEX2 On-Line Autosampler

Nova Biomedical (Waltham, MA, USA) has launched the BioProfile FLEX2 On-Line Autosampler (OLS), a modular system that connects as many as 10 bioreactors to one FLEX2 analyzer for up to three weeks of walkaway,... Read more
Copyright © 2000-2020 Globetech Media. All rights reserved.